How p53 mutations drive immunotherapy resistance—and a path to overcome it

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from researchers at the Hackensack Meridian Center for Discovery and Innovation (CDI) identifies a previously unrecognized mechanism by which mutations in the p53 gene can limit the effectiveness of immunotherapy—while also revealing a potential strategy to overcome this resistance.

Raccontata damedicalxpress.com